Novo Nordisk reports Phase III FRONTIER4 study results for denecimig

​

Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy of investigational Mim8 in patients with haemophilia A.

The post Novo Nordisk reports Phase III FRONTIER4 study results for denecimig appeared first on Hospital Management.

 

Back to the Featured Stories
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig

Featured Stories

Alteogen signs $365m Hybrozyme licensing deal with pharma company
SystImmune doses first patient in Phase III trial for ES-SCLC
SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics
Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrant
Phylo and Chugai collaborate to deploy AI platform in drug discovery

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us